Launch of Generic Lyrica

Launch of Generic Lyrica
Released: 07/24/2019   By: Heidi Dufrene, PharmD

The U.S. Food and Drug Administration (FDA) has approved the launch of generic Lyrica (pregabalin). Lyrica is a non-opioid drug used to treat neuropathic pain.

The FDA has initially granted approval for the generic version of Lyrica to nine drug companies, to include Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc. and Teva Pharmaceuticals. It is anticipated that over time, other manufacturers will enter the market, which will have a favorable impact on cost.

Generic prescription drugs approved by the FDA have the same quality and strength as brand name drugs. Generic drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Carlisle Medical encourages generic prescriptions and will notify prescribing physicians of the generic Lyrica as it becomes available in the market.

If you have any questions, please do not hesitate to contact us at